E-LIB Suche - Ergebnisse für: Cavagnaro, Joy

1

Classic and evolving approaches to evaluating cross reactiv..:

MacLachlan, Timothy K. ; Price, Shari ; Cavagnaro, Joy...
Regulatory Toxicology and Pharmacology. 121 (2021) - p. 104872 , 2021

Link: https://doi.org/10.1016/..

2

Scientific and Regulatory Policy Committee Points to Consid..:

Hutt, Julie A. ; Assaf, Basel T. ; Bolon, Brad...
Toxicologic Pathology. 50 (2021) 1 - p. 118-146 , 2021

Link: https://doi.org/10.1177/..

3

Use of an animal model of disease for toxicology enables id..:

Do, Minh-Ha Thi ; Cavagnaro, Joy ; Butt, Mark..
Regulatory Toxicology and Pharmacology. 123 (2021) - p. 104939 , 2021

Link: https://doi.org/10.1016/..

4

Report of the international conference on manufacturing and..:

Abbot, Stewart ; Agbanyo, Francisca ; Ahlfors, Jan-Eric...
Biologicals. 56 (2018) - p. 67-83 , 2018

Link: https://doi.org/10.1016/..

5

Applying a weight of evidence approach to the evaluation of..:

Rocca, Meredith ; Morford, LaRonda L. ; Blanset, Diann L....
Regulatory Toxicology and Pharmacology. 98 (2018) - p. 69-79 , 2018

Link: https://doi.org/10.1016/..

6

Considerations Regarding the Future Use of Nonhuman Primate..:

, In: The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment,

Cavagnaro, Joy A. ; Lima, Beatriz Silva - p. 649-668 , 2015

Link: https://doi.org/10.1016/..

7

Regulatory acceptance of animal models of disease to suppor..:

Cavagnaro, Joy ; Silva Lima, Beatriz
European Journal of Pharmacology. 759 (2015) - p. 51-62 , 2015

Link: https://doi.org/10.1016/..

8

Pre-clinical Specificity and Safety of UC-961, a First-In-C..:

Choi, Michael Y. ; Widhopf II, George F. ; Wu, Christina C.N....
Clinical Lymphoma Myeloma and Leukemia. 15 (2015) - p. S167-S169 , 2015

Link: https://doi.org/10.1016/..

9

Contributors:

, In: The Nonhuman Primate in Nonclinical Drug Development and Safety Assessment,

Barrow, Paul ; Bayne, Kathryn ; Bluemel, Joerg... - p. xiii-xv , 2015

Link: https://doi.org/10.1016/..

10

PEGylated Biopharmaceuticals: Current Experience and Consid..:

Ivens, Inge A. ; Achanzar, William ; Baumann, Andreas...
Toxicologic Pathology. 43 (2015) 7 - p. 959-983 , 2015

Link: https://doi.org/10.1177/..

11

Harmonizing standards for producing clinical-grade therapie..:

Andrews, Peter W ; Cavagnaro, Joy ; Deans, Robert...
Nature Biotechnology. 32 (2014) 8 - p. 724-726 , 2014

Link: https://doi.org/10.1038/..

12

Charting a Clear Path: The ASGCT Standardized Pathways Conf..:

Kiem, Hans-Peter ; Baum, Christopher ; Bushman, Frederic D...
Molecular Therapy. 22 (2014) 7 - p. 1235-1238 , 2014

Link: https://doi.org/10.1038/..

13

Considerations in the Development of Pluripotent Stem Cell-..:

, In: Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics,

Nasis, Rania ; Cunningham, Justine J. ; Brandon, Eugene P.. - p. 373-408 , 2013

Link: https://doi.org/10.1016/..

14

Contributors:

, In: Nonclinical Development of Novel Biologics, Biosimilars, Vaccines and Specialty Biologics,

Arora, Vikram ; Brandon, Eugene P. ; Cavagnaro, Joy A.... - p. xiii , 2013

Link: https://doi.org/10.1016/..

15

Practical approaches to dose selection for first-in-human c..:

Tibbitts, Jay ; Cavagnaro, Joy A. ; Haller, Christine A....
Regulatory Toxicology and Pharmacology. 58 (2010) 2 - p. 243-251 , 2010

Link: https://doi.org/10.1016/..